Navigation Links
Cynosure Appoints William T. Kelley as Senior Vice President of International Sales

Laser Industry Executive to Head Company's Network of International Subsidiaries and Distributors

WESTFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the appointment of William T. Kelley as Senior Vice President of International Sales. He will be responsible for the company's direct subsidiaries in four European countries, Japan, China and Korea, and for Cynosure distributors covering an additional 55 countries.

"Bill brings more than 25 years of experience in the medical device industry and a track record of success in growing a global distribution organization," said Michael Davin, Cynosure's President and Chief Executive Officer. "Bill has extensive background in the aesthetic and surgical laser market, and is an ideal choice to help us expand the reach of our aesthetic products around the world."

Since 2004 Kelley was director of international sales at Sciton Inc., a privately held aesthetic device company based in Palo Alto, California, where he was responsible for all business activity outside the United States. Prior to that he served as vice president and general manager for Asclepion-Meditec Inc., the surgical laser division of international optics leader Carl Zeiss AG. As vice president of worldwide sales and marketing for Summit Technology, a maker of ophthalmic excimer laser systems, he supervised the company's direct sales forces in the United States, the United Kingdom and Scandinavia as well as distributors in other regions. From 1985 to 1991 he was general manager of Pfizer Laser Systems, the surgical laser division of Pfizer Corp.

"Cynosure has worked hard to build its base of direct subsidiaries, expanding its overseas distribution network and establishing its brand as a standard of quality in more than 60 countries," Kelley said. "I am excited about the opportunity to guide its international organization and to help execute on Cynosure's strategic plan for financial and operational success."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

    Scott Solomon
    Vice President
    Sharon Merrill Associates, Inc.

SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
2. Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10
3. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
4. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
5. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
6. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
7. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
8. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
9. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
10. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
11. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men ... prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown ... helped advance the healthcare industry as a whole through their advocacy and professional ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... -- Research and Markets ( ) has announced ... 2015-2019" report to their offering. ... the author the present scenario and growth prospects of ... the market size, the report considers revenue generated from ... and copper IUDs. The report forecasts the global intrauterine ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
Breaking Medicine Technology: